InvestorLens

ABEO — ABEONA THERAPEUTICS INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ABEO?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Mixed · 2 buying vs 1 selling last quarter
46
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their ABEO position last quarter, 2 bought and 1 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Paul Tudor Jones, Ken Griffin)
  • +3 tracked investors reported holding ABEO at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About ABEONA THERAPEUTICS INC (ABEO)

ABEONA THERAPEUTICS INC (ABEO) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $15M. Across recent filings, tracked investors recorded 3 new positions, 5 increased, 8 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ABEO

50
/100
Mixed Activity
Added / Increased8
Reduced8
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track ABEO

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

ABEO Ownership Composition

How ABEONA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
65% of tracked value
Institutions
3
tracked investors
Total Reported
$6.3M
combined 13F value
Types2
  • Multi-Strategy / Quant64.9%
  • Macro35.1%
Multi-Strategy / Quant(2)
64.9%
Macro(1)
35.1%

Tracked investors currently reporting ABEO

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    211.3K
    Value
    $1.3M
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    454.4K
    Value
    $2.8M
    % Portfolio
    0.00%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    360.8K
    Value
    $2.2M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold ABEO?
3 tracked institutional investors disclosed a position in ABEO (ABEONA THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of ABEO?
Izzy Englander, Millennium Management, holds the largest disclosed position in ABEO, valued at $15M.
Did institutional ownership of ABEO increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 5 increased, 8 reduced, and 0 fully exited ABEO.
Where does this ABEO ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.